8th Oct 2007 07:00
Hikma Pharmaceuticals Plc08 October 2007 Block Listing of Shares Hikma Pharmaceuticals PLC LONDON, 8 October 2007 - The Board of Hikma Pharmaceuticals PLC ("Hikma") (LSE:HIK) (DIFX: HIK), the multinational pharmaceuticals group, announces that it hasmade a block listing application to the Financial Services Authority and theLondon Stock Exchange plc for a total of 2,432,400 ordinary shares of 10p eachin the capital of the Company to be admitted to the Official List of the UKListing Authority and admitted to trading on the main market of the London StockExchange. The shares, when issued, will be issued fully paid and rank pari passu in allrespects with the existing issued ordinary shares of the Company. The shares maybe issued pursuant to the exercise of options under the Hikma PharmaceuticalsPLC 2004 Stock Option Plan (the "Plan"). Participants in the Plan have or willbecome entitled to these shares following the vesting and exercise of optionsover shares. It is expected that admission will be granted on 11 October 2007. For further information, please contact: Henry Knowles, Company SecretaryHikma Pharmaceuticals PLC +44 20 7399 2760 Susan Ringdal, Investor Relations DirectorHikma Pharmaceuticals PLC +44 20 7399 2760 About Hikma Hikma Pharmaceuticals PLC is a fast growing multinational group focused ondeveloping, manufacturing and marketing a broad range of both branded andnon-branded generic and in-licensed products. Hikma operates through threebusinesses: "Branded", "Injectables" and "Generics", based principally in theMiddle East and North Africa ("MENA"), where it is a market leader and sellsacross 18 countries, the United States and Europe. In 2006, Hikma achievedrevenues of $317 million (2005 $262 million) and profit attributable toshareholders was $55 million (2005 $44 million). At 31 December 2006, the Grouphad over 2,400 employees. For news and other information, please visitwww.hikma.com. This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Hikma Pharmaceuticals